Current status of genomic testing and treatment for biliary tract cancer

DOI 1 Citations
  • Sasaki Takashi
    Department of Hepato-Biliary-Pancreatic Medicine, Gastroenterology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research
  • Ozaka Masato
    Department of Hepato-Biliary-Pancreatic Medicine, Gastroenterology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research
  • Sasahira Naoki
    Department of Hepato-Biliary-Pancreatic Medicine, Gastroenterology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research

Bibliographic Information

Other Title
  • 胆道癌における遺伝子診断・治療の現況

Search this article

Description

<p>Drug therapy plays a major role in the treatment of advanced biliary tract cancer, but its efficacy and treatment option are limited. Therefore, further development is indispensable for improving the overall prognosis of this cancer. Precision medicine, which examines genetic alterations in cancer and treat it with molecular targeted agents, is a new treatment option which is particularly expected for biliary tract cancer. Recently, several FGFR inhibitors and IDH inhibitors showed good efficacies and tolerability for advanced intrahepatic cholangiocarcinoma. In Japan, a cancer multi-gene panel testing has been approved by public insurance, and it is expected that treatment based on genetic alteration will further develop in the field of biliary tract cancer. However, there are many issues that needed to be resolved in the near future, such as the time until the results of genomic testing are obtained, the way to gain a sufficient volume of sample in inoperable cases, the lack of effective therapeutic agents for genetic alterations, and the cost of genomic testing.</p>

Journal

  • Tando

    Tando 34 (4), 663-671, 2020-10-31

    Japan Biliary Association

Citations (1)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top